Last reviewed · How we verify

VELCADE Administered by intravenous infusion

Millennium Pharmaceuticals, Inc. · Phase 3 active Small molecule

VELCADE Administered by intravenous infusion is a Proteasome inhibitor Small molecule drug developed by Millennium Pharmaceuticals, Inc.. It is currently in Phase 3 development for Multiple myeloma, Mantle cell lymphoma.

VELCADE (bortezomib) is a proteasome inhibitor that blocks the degradation of proteins, causing cancer cells to accumulate toxic protein levels and undergo apoptosis.

VELCADE (bortezomib) is a proteasome inhibitor that blocks the degradation of proteins, causing cancer cells to accumulate toxic protein levels and undergo apoptosis. Used for Multiple myeloma, Mantle cell lymphoma.

At a glance

Generic nameVELCADE Administered by intravenous infusion
SponsorMillennium Pharmaceuticals, Inc.
Drug classProteasome inhibitor
Target26S proteasome
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Bortezomib selectively and reversibly inhibits the 26S proteasome, a cellular complex responsible for protein degradation. By blocking proteasome function, the drug causes accumulation of pro-apoptotic proteins and disrupts cell cycle regulation, leading to cancer cell death. This mechanism is particularly effective in multiple myeloma and certain lymphomas where proteasome inhibition triggers rapid apoptosis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about VELCADE Administered by intravenous infusion

What is VELCADE Administered by intravenous infusion?

VELCADE Administered by intravenous infusion is a Proteasome inhibitor drug developed by Millennium Pharmaceuticals, Inc., indicated for Multiple myeloma, Mantle cell lymphoma.

How does VELCADE Administered by intravenous infusion work?

VELCADE (bortezomib) is a proteasome inhibitor that blocks the degradation of proteins, causing cancer cells to accumulate toxic protein levels and undergo apoptosis.

What is VELCADE Administered by intravenous infusion used for?

VELCADE Administered by intravenous infusion is indicated for Multiple myeloma, Mantle cell lymphoma.

Who makes VELCADE Administered by intravenous infusion?

VELCADE Administered by intravenous infusion is developed by Millennium Pharmaceuticals, Inc. (see full Millennium Pharmaceuticals, Inc. pipeline at /company/millennium-pharmaceuticals-inc).

What drug class is VELCADE Administered by intravenous infusion in?

VELCADE Administered by intravenous infusion belongs to the Proteasome inhibitor class. See all Proteasome inhibitor drugs at /class/proteasome-inhibitor.

What development phase is VELCADE Administered by intravenous infusion in?

VELCADE Administered by intravenous infusion is in Phase 3.

What are the side effects of VELCADE Administered by intravenous infusion?

Common side effects of VELCADE Administered by intravenous infusion include Peripheral neuropathy, Thrombocytopenia, Neutropenia, Anemia, Nausea, Diarrhea.

What does VELCADE Administered by intravenous infusion target?

VELCADE Administered by intravenous infusion targets 26S proteasome and is a Proteasome inhibitor.

Related